Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

10.37
-0.3550-3.31%
Volume:762.82K
Turnover:7.99M
Market Cap:2.27B
PE:-7.33
High:10.89
Open:10.89
Low:10.33
Close:10.72
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:185.00M
Volume Ratio:0.42
T/O Rate:0.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4140
EPS(LYR):-1.4203
ROE:-72.99%
ROA:-34.95%
PB:4.36
PE(LYR):-7.30

Loading ...

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 15

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 15

EyePoint's late-stage eye drug trials to continue after safety panel review

Reuters
·
May 14

A Look At Ocular Therapeutix (OCUL) Valuation After Recent Share Price Pullback

Simply Wall St.
·
May 13

BRIEF-Ocular Therapeutix reports inducement grants under Nasdaq listing rule 5635(C)(4)

Reuters
·
May 09

Ocular Therapeutix grants 12 new hires options for 127,650 shares, RSUs for 41,550 shares

Reuters
·
May 09

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 09

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

MT Newswires Live
·
May 07

Ocular Therapeutix Price Target Maintained With a $30.00/Share by RBC Capital

Dow Jones
·
May 06

Ocular Therapeutix (OCUL) Gets a Buy from Chardan Capital

TIPRANKS
·
May 06

Analyst Reiterates Buy Rating on OCUL, Keeps Axpaxli-Driven Price Target Unchanged at $18

TIPRANKS
·
May 06

Stock Track | Ocular Therapeutix Plummets 6.86% Intraday After Q1 Earnings Miss Estimates

Stock Track
·
May 06

Stock Track | Ocular Therapeutix Plunges 6.45% in Pre-Market After Q1 Earnings Miss Estimates

Stock Track
·
May 05

Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)

TIPRANKS
·
May 05

Earnings Flash (OCUL) Ocular Therapeutix Posts Q1 Loss $0.40 a Share, vs. FactSet Est of $0.31 Loss

MT Newswires Live
·
May 05

Ocular Therapeutix Q1 EPS $(0.40) Misses $(0.33) Estimate, Sales $10.785M Miss $12.599M Estimate

Benzinga Earnings
·
May 05

Ocular Therapeutix Inc - Cash and Cash Equivalents of $666.7 Mln as of March 31, 2026,Expected Runway Into 2028

THOMSON REUTERS
·
May 05

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

GlobeNewswire
·
May 05

What Ocular Therapeutix (OCUL)'s SOL-X Long-Term AXPAXLI Extension Study Means For Shareholders

Simply Wall St.
·
May 02

Ocular Therapeutix announces annual shareholder meeting

Reuters
·
May 01